Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 1,923 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 1,923 shares of the stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $79.77, for a total transaction of $153,397.71. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $61,245,810.60. This trade represents a 0.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Wednesday, June 3rd, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.07, for a total transaction of $690,700.00.
• On Monday, June 1st, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $67.58, for a total transaction of $1,351,600.00.
• On Wednesday, May 13th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.19, for a total value of $691,900.00.
• On Tuesday, May 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $71.75, for a total value of $1,435,000.00.

Halozyme Therapeutics Trading Down 2.2%

Shares of HALO stock traded down $1.75 during mid-day trading on Thursday, hitting $78.62. The company’s stock had a trading volume of 1,782,676 shares, compared to its average volume of 1,812,456. The company has a market cap of $9.33 billion, a PE ratio of 28.28, a P/E/G ratio of 0.34 and a beta of 0.84. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The company’s fifty day simple moving average is $70.33 and its 200-day simple moving average is $69.79. Halozyme Therapeutics, Inc. has a 52 week low of $55.64 and a 52 week high of $82.26.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. During the same quarter in the prior year, the company earned $1.11 EPS. The firm’s revenue for the quarter was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities research analysts expect that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on HALO shares. UBS Group reaffirmed a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, June 16th. Morgan Stanley decreased their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Finally, Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $81.60.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership increased its position in shares of Halozyme Therapeutics by 29.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after acquiring an additional 749,484 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Halozyme Therapeutics by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock valued at $141,613,000 after purchasing an additional 25,731 shares during the last quarter. Norges Bank bought a new stake in Halozyme Therapeutics during the 4th quarter worth approximately $128,201,000. William Blair Investment Management LLC bought a new stake in Halozyme Therapeutics during the 4th quarter worth approximately $124,031,000. Finally, Federated Hermes Inc. raised its stake in shares of Halozyme Therapeutics by 8.5% in the fourth quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock worth $105,972,000 after purchasing an additional 123,917 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.